 placebo-controlled double-blind two-center pilot trial Cop chronic progressive multiple sclerosis Cop effective safe previous clinical trial current trial chronic-progressive patients major end point progression units baseline disability Kurtzke Expanded Disability Status Scale control patients differences overall survival curves significant Progression rates months placebo group probabilities progressing Cop placebo significant difference months placebo Cop center Two-year progression rates secondary end points unconfirmed progression progression EDSS units significant